Prognostic Value Of NLR And LDH In The Treatment Of Advanced Esophageal Squamous Cell Carcinoma With Camrelizumab Combined With Apatinib

Objective: The objective of this study was to investigate the effects of NLR and LDH on the efficacy and prognosis of advanced Esophageal Squamous Cell Carcinoma(ESCC)treated with Camrelizumab combined with Apatinib before treatment,and to evaluate their significance in clinical treatment of ESCC.Methods: A retrospective analysis was performed on 46 patients who received Camrelizumab combined with Apatinib in ESCC treatment at the Affiliated Cancer Hospital of Xinjiang Medical University from December 2019 to December 2022.Data indexes of NLR and LDH before treatment were collected to analyze the relationship between NLR and LDH before treatment and various clinical features,efficacy and overall survival.Results: The AUC of NLR and LDH before treatment was 0.691 and 0.673,respectively,with an optimal cut-off value of 3.275 and 157.5.Univariate results showed that ECOG score(P=0.029),NLR(P=0.045)and LDH(P=0.008)were independent predictors of OS.Multiple factors showed that ECOG score(P=0.034)and pre-treatment LDH(P=0.027)were independent predictors of OS.Conclusion: Low NLR and LDH before treatment may predict patients’ sensitivity to treatment and better efficacy,while patients with high NLR and LDH before treatment may have shorter OS.Therefore,patient NLR and LDH levels may be a biological indicator to predict the efficacy and prognosis of ESCC in combined immunotargeted therapy.